Insider Selling: TransMedics Group (NASDAQ:TMDX) Director Sells $524,294.22 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director David Weill sold 3,571 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $146.82, for a total transaction of $524,294.22. Following the sale, the director owned 12,134 shares of the company’s stock, valued at approximately $1,781,513.88. This represents a 22.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

TransMedics Group Stock Performance

TMDX stock opened at $129.80 on Monday. The company has a market cap of $4.45 billion, a P/E ratio of 26.49 and a beta of 1.98. TransMedics Group, Inc. has a 1 year low of $62.23 and a 1 year high of $156.00. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59. The stock’s fifty day moving average price is $135.35 and its 200-day moving average price is $126.96.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Morgan Stanley raised their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Piper Sandler upped their price target on shares of TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Needham & Company LLC increased their price objective on shares of TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. JPMorgan Chase & Co. raised their price objective on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Finally, Oppenheimer boosted their target price on shares of TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $150.67.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently modified their holdings of the company. Intech Investment Management LLC raised its holdings in TransMedics Group by 28.9% during the second quarter. Intech Investment Management LLC now owns 34,389 shares of the company’s stock valued at $4,608,000 after acquiring an additional 7,713 shares during the period. Nordea Investment Management AB bought a new position in shares of TransMedics Group in the third quarter worth about $4,070,000. Peregrine Capital Management LLC grew its position in shares of TransMedics Group by 16.5% during the third quarter. Peregrine Capital Management LLC now owns 68,406 shares of the company’s stock worth $7,675,000 after purchasing an additional 9,676 shares in the last quarter. Intrust Bank NA purchased a new stake in shares of TransMedics Group during the second quarter worth about $747,000. Finally, Citigroup Inc. grew its position in shares of TransMedics Group by 29.3% during the third quarter. Citigroup Inc. now owns 76,785 shares of the company’s stock worth $8,615,000 after purchasing an additional 17,414 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.